A clinical and experimental study showed that patients with GPX4-positive diffuse large B-cell lymphoma had significantly poor progression-free survival and overall survival compared with those of the GPX4-negative group by immunohistochemistry results (119). This evidence concerns the gene GPX4 and diffuse large B-cell lymphoma.